What is Aquestive Therapeutics, Inc.'s R&D?

Aquestive Therapeutics, Inc. (AQST) reported R&D of $4.2M in Q1 2026.

How has Aquestive Therapeutics, Inc.'s R&D changed year-over-year?

Aquestive Therapeutics, Inc.'s R&D decreased by 21.6% year-over-year, from $5.36M to $4.2M.

What is the long-term trend for Aquestive Therapeutics, Inc.'s R&D?

Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s R&D has grown at a 0.2% compound annual growth rate (CAGR), from $17.05M to $17.19M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Aquestive Therapeutics, Inc. AQST R&D

R&D at other companies

Indivior Pharmaceuticals, Inc. INDV

$16M-27.3%

ARS Pharmaceuticals, Inc.SPRY

$4.34M+46.9%

ViatrisVTRS

$248.6M+12.0%

AMP

Amphastar PharmaceuticalsAMPH

$26.74M+33.0%

RegenxbioRGNX

$57.34M+8.0%

Avalo TherapeuticsAVTX

$14.05M+54.0%

Segments

By product

See full

Personnel costs$1.3M-38.1%

Anaphylm project expenses$1.21M-40.1%

Other$443K-44.0%

AQST-108 project expenses$243K+12,050%

By segment

See full

Reportable Segment$4.2M-21.6%

Other financials

Income statement

See full

Revenue$14.4M+65.7%

Gross profit$11.0M+117%

Operating income-$4.2M+78.3%

Net income-$8.1M+64.9%

EPS (diluted)-$0.07+70.8%

Balance sheet

See full

Cash & equivalents$110.7M+61.3%

Total debt$64.4M+7.4%

Total equity-$34.1M+44.1%

Total assets$141.1M+38.0%

Cash flow

See full

Operating cash flow-$14.8M+36.7%

CapEx$52.0K-61.5%

Free cash flow-$14.9M+36.9%

Valuation

See full

Market cap$560.13M+73.5%

Enterprise value$513.76M+63.6%

P/S11.1×+5.2×

Profitability

See full

Gross margin63.5%-4.9pp

Operating margin-111.2%+96.3pp

Net margin-137.1%+80.7pp

FCF margin-88.2%-2.2pp

Returns & leverage

See full

Return on equity145.1%—

Debt / equity-1.9×—

Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s R&D?: Aquestive Therapeutics, Inc. (AQST) reported R&D of $4.2M in Q1 2026.
How has Aquestive Therapeutics, Inc.'s R&D changed year-over-year?: Aquestive Therapeutics, Inc.'s R&D decreased by 21.6% year-over-year, from $5.36M to $4.2M.
What is the long-term trend for Aquestive Therapeutics, Inc.'s R&D?: Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s R&D has grown at a 0.2% compound annual growth rate (CAGR), from $17.05M to $17.19M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.